ID

13529

Descrição

Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115); ODM derived from: https://clinicaltrials.gov/show/NCT01026870

Link

https://clinicaltrials.gov/show/NCT01026870

Palavras-chave

  1. 13/02/2016 13/02/2016 -
Transferido a

13 de fevereiro de 2016

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0

Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Asthma NCT01026870

Eligibility Asthma NCT01026870

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01026870
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
an adult or adolescent subject with a diagnosis of persistent asthma of >=6 months duration may be selected for this study.
Descrição

adolescent; persistent asthma

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0205653
UMLS CUI [2]
C3266628
both subject (and/or parent/guardian, if appropriate) and investigator must agree that changing therapy is acceptable and poses no inherent risk.
Descrição

Therapy change

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3665894
subject must have been using a low daily maintenance dose of inhaled corticosteroids (ics), with or without added long-acting β2-agonist (laba), for >=12 weeks prior to screening, and must have been on a stable regimen (daily dose unchanged) for at least the last 2 weeks of that period.
Descrição

inhaled corticosteroids; Adrenergic beta-2 Receptor Agonists; regimen

Tipo de dados

boolean

Alias
UMLS CUI [1]
C3248292
UMLS CUI [2]
C2936789
UMLS CUI [3]
C0040808
at screening, the subject must have a prebronchodilator fev1 between 60% and 90% of the predicted value when restricted medications have been withheld.
Descrição

prebronchodilator fev1

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1276012
to be randomized, the subjects must be symptomatic with fev1 at baseline must be between 50% and 85% of predicted.
Descrição

fev1

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0802965
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
a subject must not have been admitted to the hospital for management of airway obstruction within the last 3 months prior to screening, and must not have experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication, as judged by the clinical investigator at any time from screening to baseline/randomization.
Descrição

Airway Management; Airway Obstruction; Hospitalization

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0150126
UMLS CUI [2]
C0001883
UMLS CUI [3]
C0019993
in addition, a subject must not have demonstrated a decrease in absolute fev1 of >20% at any time from screening to baseline, or a decrease in am peak expiratory flow (pef) below the pef stability limit on any 2 consecutive days prior to baseline/randomization.
Descrição

peak expiratory flow

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0030735

Similar models

Eligibility Asthma NCT01026870

  1. StudyEvent: Eligibility
    1. Eligibility Asthma NCT01026870
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
adolescent; persistent asthma
Item
an adult or adolescent subject with a diagnosis of persistent asthma of >=6 months duration may be selected for this study.
boolean
C0205653 (UMLS CUI [1])
C3266628 (UMLS CUI [2])
Therapy change
Item
both subject (and/or parent/guardian, if appropriate) and investigator must agree that changing therapy is acceptable and poses no inherent risk.
boolean
C3665894 (UMLS CUI [1])
inhaled corticosteroids; Adrenergic beta-2 Receptor Agonists; regimen
Item
subject must have been using a low daily maintenance dose of inhaled corticosteroids (ics), with or without added long-acting β2-agonist (laba), for >=12 weeks prior to screening, and must have been on a stable regimen (daily dose unchanged) for at least the last 2 weeks of that period.
boolean
C3248292 (UMLS CUI [1])
C2936789 (UMLS CUI [2])
C0040808 (UMLS CUI [3])
prebronchodilator fev1
Item
at screening, the subject must have a prebronchodilator fev1 between 60% and 90% of the predicted value when restricted medications have been withheld.
boolean
C1276012 (UMLS CUI [1])
fev1
Item
to be randomized, the subjects must be symptomatic with fev1 at baseline must be between 50% and 85% of predicted.
boolean
C0802965 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Airway Management; Airway Obstruction; Hospitalization
Item
a subject must not have been admitted to the hospital for management of airway obstruction within the last 3 months prior to screening, and must not have experienced an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with additional, excluded asthma medication, as judged by the clinical investigator at any time from screening to baseline/randomization.
boolean
C0150126 (UMLS CUI [1])
C0001883 (UMLS CUI [2])
C0019993 (UMLS CUI [3])
peak expiratory flow
Item
in addition, a subject must not have demonstrated a decrease in absolute fev1 of >20% at any time from screening to baseline, or a decrease in am peak expiratory flow (pef) below the pef stability limit on any 2 consecutive days prior to baseline/randomization.
boolean
C0030735 (UMLS CUI [1])

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial